Division of Allergy, Immunology, and Rheumatology, Department of Medicine, Kaohsiung Veterans General Hospital, No.386, Dazhong 1st Rd., Zuoying District, Kaohsiung City, Taiwan.
Division of Pulmonary Medicine, Department of Internal Medicine, Shuang Ho Hospital, Taipei Medical University, No. 291, Zhongzheng Rd, Zhonghe District, New Taipei City, Taiwan; Division of Pulmonary Medicine, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, No. 250, Wuxing Street, Xinyi District, Taipei City, Taiwan.
Cytokine Growth Factor Rev. 2022 Feb;63:34-43. doi: 10.1016/j.cytogfr.2022.01.001. Epub 2022 Jan 13.
Recent studies have identified an association between perturbed type I interferon (IFN) responses and the severity of coronavirus disease 2019 (COVID-19). IFNα intervention may normalize the dysregulated innate immunity of COVID-19. However, details regarding its utilization and therapeutic evidence have yet to be systematically evaluated. The aim of this comprehensive review was to summarize the current utilization of IFNα for COVID-19 treatment and to explore the evidence on safety and efficacy. A comprehensive review of clinical studies in the literature prior to December 1st 2021, was performed to identify the current utilization of IFNα, which included details on the route of administration, the number of patients who received the treatment, the severity at the initiation of treatment, age range, the time from the onset of symptoms to treatment, dose, frequency, and duration as well as safety and efficacy. Encouragingly, no evidence was found against the safety of IFNα treatment for COVID-19. Early intervention, either within five days from the onset of symptoms or at hospital admission, confers better clinical outcomes, whereas late intervention may result in prolonged hospitalization.
最近的研究表明，I 型干扰素（IFN）反应失调与 2019 年冠状病毒病（COVID-19）的严重程度有关。IFNα 干预可能使 COVID-19 失调的固有免疫正常化。然而，其使用细节和治疗证据尚未得到系统评估。本综述的目的是总结 IFNα 治疗 COVID-19 的当前应用，并探讨其安全性和疗效证据。对截至 2021 年 12 月 1 日的文献中的临床研究进行了全面回顾，以确定 IFNα 的当前应用，包括给药途径、接受治疗的患者人数、治疗开始时的严重程度、年龄范围、从症状出现到治疗的时间、剂量、频率和持续时间以及安全性和疗效的详细信息。令人鼓舞的是，没有发现 IFNα 治疗 COVID-19 的安全性有问题。早期干预，即症状出现后 5 天内或住院时进行干预，可获得更好的临床结果，而晚期干预可能导致住院时间延长。
